NCT06757348Not yet recruiting
Fatty Liver and Pancreatic Steatosis
Association Between Fatty Liver and Pancreatic Steatosis in Patients With Metabolic Syndrome
Source: ClinicalTrials.gov · Last updated 6 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to determine the prevalence of pancreatic steatosis in patients with fatty liver and determine the prevalence of exocrine pancreatic insufficiency (EPI) in these patients. Participants with fatty liver and metabolic syndrome will undergo fecal elastase measurement and endoscopic ultrasound (EUS).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 61 (estimated)
- First submitted
- 22 Oct 2024
- Start date
- 1 Sept 2025
- Primary completion date
- 1 Mar 2026
- Lead sponsor
- Maria Marta Piskorz
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT06757348
What you commit to
- Study type: Observational
- Planned participants: 61
- From 1 Sept 2025 to the primary completion date, 1 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Chronic hepatitis B or C infection
- Autoimmune liver diseases: autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis
- Wilson's disease
- Celiac disease
- Uncontrolled thyroid disease
- Active or chronic infectious disease
- Active cancer or ongoing treatment
- Chronic renal insufficiency
Other
- \- Alcohol consumption \>20 g/day in women, \>30 g/day in men
- Hereditary hemochromatosis
- Alpha-1 antitrypsin deficiency
- Pregnancy/lactation
- Insufficient data
- Patients who do not complete follow-up
Who the study is looking for
- Patients over 18 years old with a diagnosis of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital de Clinicas Jose de San Martin Coordinator of this site? Confirm its status | Ciudad Autonoma de Buenos Aires | Argentina | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.